Portada Simposios - Supplements - Haematologica

XLII Reunión Nacional de la AEHH y XVI Congreso de la SETH. Simposios
223
ción de PCR [p. ej. t(8,21) y t(15;17)] 85-87 . Sin embargo,
el número de pacientes analizado es escaso y
necesita ser optimizada y estandarizada para poder
establecer su utilidad clínica, especialmente con vistas
a la toma de decisiones terapéuticas.
Conclusión
En el momento actual los hematólogos disponemos
de una importante batería de marcadores que
proporcionan información relevante sobre el pronóstico
de las LMA. Una premisa fundamental sería
utilizarlos simultáneamente y de manera prospectiva,
en series de enfermos que van a ser tratados con
protocolos uniformes, para poder establecer modelos
predictivos, que ulteriormente permitieran estratificar
el tratamiento en función del riesgo. Además
estos modelos, serían la base para nuevos ensayos
terapéuticos, pues todo ensayo, especialmente
aquellos que incluyen nuevas drogas, debería llevarse
a cabo en grupos de enfermos bien definidos en
cuanto a sus características clínico-biológicas, ya
que ello facilitaría poder identificar quien se beneficia
y quien no de esa opción terapéutica experimental.
Bibliografía
1. Mandelli Franco, Petti MC, Lo Coco F. Therapy of acute myeloid leuklemia:
towards a patient-oriented, risk-adapted approach. Haematologica
1998; 83: 1015-1023.
2. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl
J Med 1999; 341: 1051-1062.
3. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörman B
et al. Management of acute myeloid leukeima in elderly patients. J Clin
Oncol 1999; 17: 3569-3576.
4. Filipits M, Stranzl T, Pohl G, Heinzl H, Jäger U, Geissler K et al. Drug
resistance factors in acute myeloid leukemia: a comparative analysis.
Leukemia 2000; 14: 68-76.
5. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, Head DR et al.
Frequency and clinical significance of expression of the multidrug resistance
proteins MDR1/P-glycoprotein, MRP and LRP in acute myeloid
leukemia patients less than 65 years of age: A Southwest oncology
group study. Blood 1999; 94: 1086-1099.
6. Grimwade D, Walker H, Oliver F, Weatkey K, Harrinson C, Harrinson G,
Rees J, Hann, I, Stevens R, Burnett A, Goldstone A on behalf of the
Medical Research Council Adult and Children’s Leukaemia Working
parties. The importance of diagnostic cytogenetics on outcome in
AML: analysis of 1,612 patients entered into the MRC AML 10 trial.
Blood 1998; 92: 2322-2333.
7. Gahn B, Haase D, Unterhalt M et al. De novo AML with dysplastic hematopoiesis:
cytogenetic and prognostic significance. Leukemia 1996;
10: 946-951.
8. Harris LN, Jaffe E, Dielbold J, Flandin G, Muller-Hermelink KH, Vardiman
J et al. World wealth organization classification of neoplastic diseases
of the hematopoietic diseases and lymphoid tissues: Report of
the clinical advisory committee meeting. Airline House, Virginia, November
1997. J Clin Oncol, 1999; 17: 3835-3849.
9. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann YM, Harrison
CJ, Rees J. KH, Stevens RF, Walker H on behalf of the United Kingdom
Medical Research Council’s Adult and Childhood Leukemia working
parties. A simple, robust, validated and highly predictive index for
the determination of risk-directed therapy in acute myeloid leukaemia
derived from the MRC AML 10 trial. Br J Haematol 1999; 10:
69-79.
10. Vallespí T, Vidriales B, González I, Cañizo MC, Orfao A, Martínez A et
al. La morfología óptica convencional en la evaluación de la remisión
tras el tratamiento de inducción. Comparación con otros métodos. Impacto
sobre la evolución. Hematologica 1998; 83: 383-386.
11. Cañizo MC, Mota A, Orfao A, Galende J, Caballero MD, García Marcos
MA et al. Value of colony forming unit-granulocyte macrophage assay
in predicting relapse in acute myeloid leukemia. J Clin Pathol 1996;
49: 450-452.
12. Estey EH, Shen Y, Thall P F. Effect of time to complete remission on
subsequent survival and disease-free survival time in AML, RAEB-t,
and RAEB. Blood 2000; 95: 72-77.
13. Estey E, Pierce S. Routine Bone Marrow Exam During First Remission of
Acute Myeloid Leukemia. Blood 1996; 87: 3899-3902.
14. Béné MC, Berner M, Castoldi G, Faure G. C, Knapp W, Ludwig WD,
Matutes E., Orfao A, Veer Van’t M on behalf of EGIL. Impact of immunophenotyping
on management of acute leukemias. Haematologica
1999; 84: 1024-1034.
15. Solary E, Casasnovas RO, Campos L et al. Surface markers in adult
acute myeloblastic leukaemia: correlation of CD19+, CD34+ and
CD14+/DR– phenotypes with shorter survival. Groupe dÉtude Immunologique
des Leucémies (GEIL). Leukemia 1992; 6: 393-399.
16. Fergedal M, Astrom M, Tidefelt U, Karlsson MG. Differences in CD14
and alpha naphthyl acetate esterase positivity and relation to prognosis
in AML. Leuk Res 1998; 22: 25-30.
17. Lanza F, Rigolin GM, Moretti S, Latorraca A, Castoldi GL. Prognostic
value of immunophenotypic characteristics of blast cells in acute myeloid
leukaemia. Leukemia and Lymphoma 1994; 13: 81-85.
18. San Miguel JF, Ojeda E, González M et al. Prognostic value of immunological
markers in acute myeloblastic leukaemia. Leukemia 1989; 3:
108-111.
19. Paietta E, Andersen J, Yunis J et al. Acute myeloid leukaemia expressing
the leucocyte integrin CD11b a new leukaemic syndrome with poor
prognosis: result of an ECOG database analysis. Br J Haematol 1998;
100: 265-272.
20. Vidriales MB, Orfao A, González M et al. Expression of NK and lymphoid-associated
antigens in blast cells of acute myeloblastic leukemia.
Leukemia 1993; 7: 2026-2029.
21. Legras S, Gunthert V, Stauder R et al. a strong expression of CD44-6v
correlated with shorter survival of patients with acute myeloblastic leukaemia.
Blood 1998; 91: 3401-3413.
22. Archimbaud E, Thomas X, Campos S, Magaud JP, Doré JF, Fiere D. Expression
of surface adhesion molecules CD54 (ICAM-1) and CD58
(LFA-3) in adult acute leukaemia relationship with initial charateristics
and prognosis. Leukemia 1992; 6: 265-271.
23. Mann KP, De Castro CM, Liu J, Moore JO, Bigner SH, Traweek T. Neural
cell adhesion molecule (CD56) positive acute myelogenous leukaemia
and myelodysplastic and myeloproliferative syndromes. Am J Pathol
1997; 107: 653-660.
24. Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R,
Rothe G, Lacombe F, Lanza F, Papa S, Lucio P, San Miguel JF, for the
standardization committee on clinical flow cytometry of the internal federation
of clinical chemistry. Clinically useful information provided by
the flow cytometric immunophenotyping of hematological malignancies:
current status and future directions. Clin Chem 1999; 45:
1708-1717.
25. Löwenberg B, van Putten WL, Touw IP et al. Autonomous proliferation
of leukemia cells in vitro as determinant of prognosis in adult acute
mieloid leukemia. N Engl J Med 1993; 328: 614-619.
26. Cañizo MC, Brufau A, Almeida J, Galende J, García Marcos MA, Mota
A et al. In vitro growth in acute myeloblastic leukemia: relationship with
other clinico-biological characteristics of the disease. Br J Haematol
1998; 103: 137-142.
27. Zhou DC, Hoang-Ngoc L, Delmer A, Faussat AM, Russo D, Zittoun R et
al. Expression of resistance genes in acute leukemia. Leuk Lymphoma
1994 (13:1), 27-30.
28. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P et al.
MDR1 gene expression and treatment outcome in acute myeloid leukemia.
J Natl Cancer Inst, 1991; 83: 708-712.
29. Gsur A, Zochbauer S, Gotzl M, Kyrle PA, Lechner K, Pirker R. MDR1
RNA expression as a prognostic factor in acute myeloid leukemia: an
update. Leuk Lymphoma 1993; 12: 91-94.
30. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F et al.
Predictive value for treatment outcome in acute myeloid leukemia of cellular
daunorubicin accumulation and P-glycoprotein expresson simultaneously
determined by flow cytometry. Blood 1995; 85: 2147-2153.
31. te Boekhorst PA, Lowenberg B, van Kapel J, Nooter K, Sonneveld P.
Multidrug resistant cells with high prolifrative capacity determine response
to therapy in acute myeloid leukemia. Leukemia 1995; 9:
1025-1031.
32. Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein
expression as unfavorable prognostic factor in caute myeloid
leukemia. Leukemia 1994; 8: 974-977.
33. Lamy T, Goasguen JE, Mordelet E, Grulois I, Dauriac C, Drenou B, et
a. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid
leukemia(AML). Leukemia 1994; 8: 1879-1883.
34. van den Heuvel-Eibrink MM, van der Holt B, te Boekhorst Paw, Pieters
R, Schoester M, Löwenberg B, Sonneveld P. MDR1 expression is an independent
prognostic factor for response and survival in de novo acute
myeloid leukaemia. Br J Haematol 1997; 99: 76-83.
35. Hart SM, Ganeshaguru K, Lyttelton MP, Prentice HG, Hoffbrand AV,
Mehta AB. Flow cytometric assessment of multidrug resistance (MDR)
phenotype in acute myeloid leukaemia. Leuk Lymphoma 1993; 11:
239-248.
36. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement
of daunorubicin accumulation, retention, and cytotoxicity
by verapamil or cyclosporin A in blast cells from patients with previously
untreated acute myeloid leukemia. Blood 1993; 82: 1288-1299.
37. Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. Over expression
of lung resistance protein and increased P-glycoprotein function in acute
myeloid leukaemia cells predict a poor response to chemotherapy
and reduced patient survival. Br J Haematol 1998; 103: 1083-1091.
38. Leith, CP, Chen IM, Kopecky J, Head R, Appelbaum FR, Godwin J. Correlation
of multidrug resistance (MDR1) protein expression with func-